Bioliography
- DAHLOF B, DEVEREUX RB,KJELDSEN SE et al.: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet (2002) 359:995–1003.
- LINDHOLM LH, IBSEN H, DAHLOF B et al.: Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet (2002) 359:1004–1010.
- HANSSON L, LINDHOLM LH, NISKANEN Let al: Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet (1999) 353:611–616.
- HANSSON L, LINDHOLM LH, EKBOM T et al: Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity in the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 354:1751-7156.
- THE HEART OUTCOMES PREVENTION EVALUATION STUDY INVESTIGATORS: Effect of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl. J. Med. (2000) 342:145–153.
- THE HEART OUTCOMES PREVENTION EVALUATION STUDY INVESTIGATORS: Effects of rarnipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet (2000) 355:253–259.
- KANNEL WB, MCGEE DL: Diabetes and cardiovascular risk factors in the Framingham study. Circulation (1979) 59:8–13.
- STAMLER L, VACCARO 0, NEATON JD, WENTWORTH D: Diabetes, other risk factors and 12-year cardiovascular mortality for men screened in Multiple Risk Factor Intervention Trial. Diabetes Care (1993) 16:434–444.
- STERGIOUS GS, SKEVA II, BAIBAS NM et al.: Additive hypotensive effect of angiotensin-converting enzyme inhibition and angiotensin-receptor antagonism in 118 essential hypertension. J Cardiovasc. Pharmacol (2000) 35:937–941.
- WAEBER B, ASCHWANDEN R, SADECKY L, FERBER P: Combination of hydrochlorothiazide or benazepril with valsartan in hypertensive patients unresponsive to valsartan alone. Hypertension (2001) 19:2097–2104.